Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases.

Request To Download Free Sample of This Strategic Report @ Highlighted with 36 tables and 83 figures, this 153-page report ?North America Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Biogen is currently squeezed between competitive pressures to its multiple sclerosis and spinal muscular atrophy products and practically zero sales of Aduhelm, so a lot is riding on its near-term ...

Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the ...

Biogen has moved to shore up its besieged multiple sclerosis franchise by licensing a BTK inhibitor from Chinese biotech InnoCare currently in mid-stage clinical testing. InnoCare gets $125 ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index, which posted a gain ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

China said Tuesday it would counter President Trump's tariffs on Chinese products with tariffs of its own on multiple U.S. imports. It also announced an antitrust investigation into Google and ...

Biogen Pharmachem Industries Ltd share price was down by -0.86% from the previous closing price of ₹1.16. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...